We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Diseases Diagnosed by Isolating Biomarkers in Tears

By LabMedica International staff writers
Posted on 25 Jul 2022

Current clinical studies pose significant challenges in distinguishing disease subtypes with accurate molecular signatures and tracking the disease progression in a non-invasive way. More...

Identifying molecular clues in samples from patients, such as specific proteins or genes from vesicular structures called exosomes, could improve the accuracy of diagnoses.

Since small extracellular vesicles (sEVs, exosomes) reveal specific functions in various biological processes, including immune regulation, angiogenesis, tumor invasion, and cell migration, exosome-based liquid biopsy technology has offered an attractive alternative to disease classification and prognostic prediction. Tears are well-suited for sample collection because the fluid can be collected quickly and non-invasively.

Medial Scientists at the Wenzhou Medical University (Wenzhou, China) and their colleagues carried out a retrospective case-controlled study that included patients with dry eye and type 2 diabetes. A tear sample was collected by placing a Schirmer paper on each eye, and the moistened length was immediately recorded after 5 minutes of collection or at completion (length reaching at 30 mm in 5 minutes).

The tear mixture was eluted from the Schirmer strip by shaking at 4 °C for 30 minutes and two-step centrifugation (200g for 10 minutes and 3,000g for 10 minutes) to remove cells and other impurities. Exosomes were subsequently purified with the rapid-isolation system under the negative pressure of 40 kPa and conversion time of 30 seconds, respectively. Samples were loaded to the equilibrated size exclusion chromatography column (qEV original, IZON Science Ltd., Oxford, UK), and 16 sequential fractions of 0.5 mL were eluted by adding PBS. The eluted fractions 8–10 were pooled and concentrated to a final volume of 150 μL. Nanoparticle Tracking Analysis (NTA) was performed on a NanoSight NS300 system (Malvern Panalytical, Malvern, UK). Other methods included in the study were Western Blot analysis, on-device exosome detection, proteomic analysis, and exosomal miRNA sequencing.

The investigators successfully distinguished between healthy controls and patients with various types of dry eye disease based on a proteomic assessment of extracted proteins. Similarly, the Incorporated Tear Exosomes Analysis via Rapid-isolation System (iTEARS) enabled the team to observe differences in microRNAs between patients with diabetic retinopathy and those that didn't have the eye condition, suggesting that the system could help track disease progression. The team says that this work could lead to a more sensitive, faster and less invasive molecular diagnosis of various diseases, using only tears.

The authors concluded that they established the iTEARS for deciphering the biomarkers of diseases from a teardrop, which revealed the promising role of tear exosomes in disease classification and course monitoring of ocular disorders and other diseases such as neurodegenerative diseases and cancer. By being applied in extended disease types and validated with abundant clinical cases, they anticipate their teardrop-based iTEARS to be the alternative tool for point-of-care-test. The study was published on July 20, 2022 in the journal ACS Nano.

Related Links:
Wenzhou Medical University 
IZON Science Ltd 
Malvern Panalytical


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.